Arrowhead Pharmaceuticals Inc. (ARWR) Tops Q2 EPS by 11c
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $83.99 +4.41%
Revenue Growth %: +89.8%
Financial Fact:
NET INCOME (LOSS): -19.42M
Today's EPS Names:
CRMT, More
Revenue Growth %: +89.8%
Financial Fact:
NET INCOME (LOSS): -19.42M
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q2 EPS of ($0.93), $0.11 better than the analyst estimate of ($1.04). Revenue for the quarter came in at $73.74 million versus the consensus estimate of $71.5 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Morgan Stanley Upgrades Galp Energia SGPS SA (GALP:LI) (GLPEF) to Overweight
- JPMorgan Starts Kanzhun Ltd (2076:HK) at Overweight
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
